Researchers found after bariatric procedures, patients lost an average of 58 pounds after two years, compared to 12 pounds ...

Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition ...

Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses ...

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...

Eli Lilly will start selling the two highest doses of its popular weight-loss drug Zepbound directly to customers online in ...

Eli Lilly expands Zepbound access with flat-rate pricing and new vial options, supporting wider obesity treatment access ...

INDIANAPOLIS, Ind. - Eli Lilly and Company, a major pharmaceutical company, announced on Monday that its weight-loss drug, ...

Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See ...

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...

Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

Experts say that semaglutide and tirzepatide can help patients with heart failure lose weight, but limited NHS access is ...

Australia's Therapeutic Goods Administration (TGA) approved the weight-loss drug Mounjaro to treat sleep apnea, a condition ...